首页> International journal of molecular sciences> Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting.

Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting.

导出 OA

翻译打印收藏纠错

第一作者： Martino,Pedrani

第一单位： Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.;Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20100 Milan, Italy.

作者： Martino,Pedrani ^[1] ; Giuseppe,Salfi ^[2] ; Sara,Merler ^[3] ; Irene,Testi ^[4] ; Chiara Maria,Agrippina Clerici ^[5] ; Giovanna,Pecoraro ^[6] ; Luis,Castelo-Branco ^[5] ; Fabio,Turco ^[5] ; Luigi,Tortola ^[5] ; Ursula,Vogl ^[5] ; Silke,Gillessen ^[7] ; Jean-Philippe,Theurillat ^[8] ; Thomas,Zilli ^[9] ; Ricardo Pereira,Mestre ^[10]

作者单位： Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.;Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20100 Milan, Italy. ^[1] Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.;Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland. ^[2] Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.;Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.;Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.;Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine, University of Verona and Verona University Hospital Trust, 37129 Verona, Italy. ^[3] Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.;Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy. ^[4] Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland. ^[5] Oncology Department, University of Naples "Federico II", 80131 Naples, Italy. ^[6] Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.;Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland. ^[7] Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.;Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland. ^[8] Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.;Department of Radiation Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.;Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland. ^[9] Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.;Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.;Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland. ^[10]

关键词 PTEN/PI3K/AKT RB1 TP53 aggressive-variant prostate cancer androgen receptor pathway inhibitors predictive prognostic prostate cancer survival tumor suppressor genes